Patent · US Active

Fibroblast growth factor 21 mutations

US9023791B2 · kind B2 · utility

31Cited by

0References

39Claims

0Family size

Assignees

Novartis AG · CH
IRM Inc. · BM

Inventors

Brian R. Boettcher · Winchester, US
Shari Lynn Caplan · Lunenburg, US
Douglas S. Daniels · Arlington, US
Bernhard Hubert Geierstanger · Solana Beach, US
Norio Hamamatsu · Belmont, US
Stuart Licht · Cambridge, US
Andreas Loew · Somerville, US
Stephen Craig Weldon · Leominster, US

Key dates

Filing date	Nov 15, 2011
Grant date	May 5, 2015
Priority date	—
Expiry date	Nov 15, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/31
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides novel polypeptide and protein variants of fibroblast growth factor 21 (FGF21) and pharmaceutical compositions comprising FGF21 polypeptide and protein variants.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.